Allogene Therapeutics Inc... (ALLO)
1.86
-0.06 (-3.12%)
At close: Jan 15, 2025, 3:59 PM
1.87
0.27%
After-hours Jan 15, 2025, 04:00 PM EST
Ratios (Annual)
Discover comprehensive ratio statement breakdowns that reveal insights into revenue, expenses, and beyond.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
| PE Ratio | -1.54 | -2.73 | -8.28 | -13.01 | -14.22 | -3.69 | -1.47M |
| PS Ratio | 5.30K | 3.71K | 52.65 | n/a | n/a | n/a | n/a |
| PB Ratio | 0.98 | 1.35 | 2.21 | 2.81 | 4.17 | 1.11 | -1.47M |
| P/FCF Ratio | -2.11 | -3.99 | -9.82 | -16.78 | -13.96 | -16.28 | n/a |
| P/OCF Ratio | -2.12 | -4.08 | -10.96 | -26.4 | -19.12 | -17.46 | n/a |
| OCF/S Ratio | -2.50K | -907.49 | -4.8 | n/a | n/a | n/a | n/a |
| Debt / Equity Ratio | 0.19 | 0.14 | 0.08 | 0.05 | 0.08 | 0.05 | n/a |
| Quick Ratio | 12.38 | 10.85 | 17.22 | 11.15 | 18.30 | 24.78 | n/a |
| Current Ratio | 12.38 | 9.70 | 16.80 | 8.96 | 16.46 | 15.89 | n/a |
| Asset Turnover | 0.00 | 0.00 | 0.04 | n/a | n/a | n/a | n/a |
| Interest Coverage | n/a | n/a | n/a | n/a | n/a | -57.43 | n/a |
| Return on Equity (ROE) | -0.64 | -0.5 | -0.27 | -0.22 | -0.29 | -0.3 | 1.00 |
| Return on Assets (ROA) | -0.51 | -0.4 | -0.24 | -0.19 | -0.26 | -0.27 | n/a |
| Return on Capital (ROIC) | -0.54 | -0.44 | -0.26 | -0.23 | -0.3 | -0.26 | 1.00 |
| Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross Profit Margin | -255.60K% | -6.78K% | 66.06% | n/a | n/a | n/a | n/a |
| Net Profit Margin | -344.49K% | -135.73K% | -636.12% | n/a | n/a | n/a | n/a |
| Pretax Profit Margin | -344.49K% | -136.89K% | -667.74% | n/a | n/a | n/a | n/a |
| Operating Profit Margin | -344.99K% | -138.04K% | -664.58% | n/a | n/a | n/a | n/a |
| FCF Margin | -251.84K% | -92.88K% | -535.89% | n/a | n/a | n/a | n/a |
| EBITDA Margin | -316.10K% | -132.20K% | -441% | n/a | n/a | n/a | n/a |